Long‐Term Effects of Myocardial Injury on 1‐Year Outcomes in Hospital Survivors With COVID‐19: A Prospective Cohort Study
MedComm · 2026-11 · 7 (11)
DOI: 10.1002/mco2.71119 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift MedComm, online erschienen am 03.11.2026. Verfasst von Wu He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji…. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Myocardial injury is both a common complication among hospitalized coronavirus disease 2019 (COVID‐19) patients and a major predictor of adverse clinical outcomes. However, its long‐term effects remain poorly defined. In this prospective cohort study of 2185 COVID‐19 survivors (531 with myocardial injury), we assessed 1‐year post‐discharge outcomes using Kaplan–Meier analysis and multivariable Cox regression before and after propensity score matching. Myocardial injury was associated with higher all‐cause mortality (adjusted hazard ratio [aHR] 3.14) and major adverse cardiovascular events (MACE) (aHR 5.22). Long‐term use of angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) was associated with reduced mortality (aHR 0.44) and MACE (aHR 0.58) in the myocardial injury group. At 1 year, 71.5% of survivors reported persistent symptoms—most commonly fatigue and sleep difficulties—and those with myocardial injury had poorer quality of life. This study provides the prospective evidence from China's Omicron era on the prognostic value of myocardial injury, combining hard clinical endpoints with patient‐reported outcomes and the first analysis of the ACEI/ARB association in this population. These findings highlight the prognostic importance of myocardial injury and the potential role of ACEI/ARB therapy in post‐discharge management, supporting targeted follow‐up strategies for this high‐risk population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College Huazhong University of Science and T…
- Department of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
He, W., He, Q., Xu, K., Li, G., Yan, Y., Yu, B., Su, Y., Wu, J., Wang, H., & Wang, D. W. (2026). Long‐Term Effects of Myocardial Injury on 1‐Year Outcomes in Hospital Survivors With COVID‐19: A Prospective Cohort Study. MedComm, 7(11). https://doi.org/10.1002/mco2.71119
Vancouver
He W, He Q, Xu K, Li G, Yan Y, Yu B, et al. Long‐Term Effects of Myocardial Injury on 1‐Year Outcomes in Hospital Survivors With COVID‐19: A Prospective Cohort Study. MedComm. 2026;7(11). doi:10.1002/mco2.71119
BibTeX
@article{He2026,
author = {He, Wu and He, Qiongyao and Xu, Ke and Li, Gen and Yan, Yongcui and Yu, Bo and Su, Yujing and Wu, Junfang and Wang, Hong and Wang, Dao Wen},
title = {Long‐Term Effects of Myocardial Injury on 1‐Year Outcomes in Hospital Survivors With COVID‐19: A Prospective Cohort Study},
journal = {MedComm},
year = {2026},
volume = {7},
number = {11},
doi = {10.1002/mco2.71119}
}
EUVIMED